These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 36346716)

  • 1. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
    Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
    Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
    Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
    Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
    JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcomes for borderline resectable adenocarcinoma of the pancreas after neoadjuvant chemotherapy in a community cancer center.
    Curto EM; Kaza AG; Sturdevant DA; Tuvin DM; Ganai S; Sticca RP
    Am J Surg; 2022 Dec; 224(6):1426-1431. PubMed ID: 36372580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Lee YN; Sung MK; Hwang DW; Park Y; Kwak BJ; Lee W; Song KB; Lee JH; Yoo C; Kim KP; Chang HM; Ryoo BY; Kim SC
    Cancer Res Treat; 2024 Oct; 56(4):1240-1251. PubMed ID: 38901824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Treatment for Pancreatic Cancer.
    Raufi AG; Manji GA; Chabot JA; Bates SE
    Semin Oncol; 2019 Feb; 46(1):19-27. PubMed ID: 30630600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy.
    Ivey GD; Shoucair S; Delitto DJ; Habib JR; Kinny-Köster B; Shubert CR; Lafaro KJ; Cameron JL; Burns WR; Burkhart RA; Thompson EL; Narang A; Zheng L; Wolfgang CL; He J
    World J Surg; 2022 Nov; 46(11):2751-2759. PubMed ID: 35861852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
    Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
    J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderline Resectable Pancreatic Adenocarcinoma.
    Ross SB; Popover J; Sucandy I; Christodoulou M; Pattilachan TM; Rosemurgy AS
    Am Surg; 2024 Nov; 90(11):3061-3073. PubMed ID: 38635295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials.
    Aliseda D; Martí-Cruchaga P; Zozaya G; Blanco N; Ponz M; Chopitea A; Rodríguez J; Castañón E; Pardo F; Rotellar F
    BJS Open; 2024 Sep; 8(5):. PubMed ID: 39329454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    Am Surg; 2022 Dec; 88(12):2899-2906. PubMed ID: 33861651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.